Date: 2015-09-28
Type of information: Nomination
Compound:
Company: Ziopharm Oncology (USA - MA)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details: * On September 28, 2015, Ziopharm Oncology, a biopharmaceutical company focused on the development and commercialization of new cancer immunotherapies,announced the appointment of Scott Tarriff to the Company\'s Board of Directors. Mr. Tarriff, who serves as President, Chief Executive Officer and a Director of Eagle Pharmaceuticals, brings more than 25 years of pharmaceutical industry experience to Ziopharm. Mr. Tarriff is the Founder, President, and Chief Executive Officer of Eagle Pharmaceuticals, a specialty pharmaceutical company focused on developing and commercializing injectable products. Prior to joining Eagle, Mr. Tarriff held various executive positions at Par Pharmaceutical Companies, Inc. including serving as President and Chief Executive Officer from September 2003 to September 2006, after joining Par in 1998. Mr. Tarriff also served on Par\'s Board of Directors from 2002 to September 2006. Prior to that, Mr. Tarriff held various positions with Bristol-Meyers Squibb, a publicly-traded biopharmaceutical company, including Senior Director of Marketing. Mr. Tarriff has served as a director of Synthetic Biologics, Inc., a publicly traded biotechnology company, since February 2012 and previously served on the Board of Directors of Clinical Data, Inc., a publicly-traded pharmaceutical company, from September 2009 to April 2011 when Clinical Data was acquired by Forest Laboratories, Inc. Mr. Tarriff holds a M.B.A. from Rider College and a B.S. in marketing from Pennsylvania State University.
Financial terms:
Latest news:
